Research study Program year 2023 Source: CMS Open Payments

EYE DMI Epidemiology Study

Research payments

$146,655

16 payments

Through program year 2023, $146,655 in research payments was reported against EYE DMI Epidemiology Study, across 16 payments, paid by Boehringer Ingelheim International GmbH.

Paid by: Boehringer Ingelheim International GmbH
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2023	Research	$28,219	8
2022	Research	$118,436	8

Breakdown

Who paid Research payments · program years 2022–2023

Boehringer Ingelheim International GmbH $146,655 16 payments

Who received the money Research payments · program years 2022–2023

Clear Vue Laser Eye Center Inc Organisation paid for research $37,396 2 payments
Nwn Univ Organisation paid for research $32,150 2 payments
Tufts Medical Center Organisation paid for research $21,442 2 payments
West Coast Retina Medical Group INC Organisation paid for research $16,793 2 payments
Washington University School Of Medicine Organisation paid for research $14,380 2 payments
Joslin Diabetes Center Organisation paid for research $12,262 2 payments
Stanford University Medical Center Organisation paid for research $8,553 2 payments
David Geffen School Of Medicine At UCLA Organisation paid for research $3,679 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

8 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.